CBD could be one of the biggest investment stories of 2021. Not only are retailers, like Sephora, Vitamin Shopped, CVS, and Walgreen’s stocking shelves with CBD products, we’re just now seeing a significant shift in consumer attitudes. For example a Gallup poll shows support at a new high of 68% up from 66% year over year. Better, analysts at Nielsen say CBD product sales could reach $6.9 billion by 2025.
In addition, according to CNBC, Senate Majority Leader Chuck Schumer, Sens. Cory Booker, D-N.J., and Ron Wyden, D-Ore., have plans to release a new omnibus cannabis reform bill that will tackle de-scheduling and/or decriminalization of cannabis at the federal level.
That Could Help Drive Big Interest in CBD-Related Companies
Pure Extracts Technologies Corp.(CSE:PULL)(OTC:PRXTF)(XFRA:A2QJAJ), for example, just announced that it recently contracted its first commercial sale of CBD oil. Pure Extracts is preparing to deliver the first of what it believes will be multiple shipments this year of its 85% pure CBD distillate under this contract. The Company’s high purity distillate is ideally suited for use in most cannabis 2.0 products including edibles, vape pens and beverages.
Pure Extracts uses its state-of-the art sub-critical/super-critical CO2 extraction system to create exceptionally pure THC and CBD full spectrum oil and distillate in order to meet the rigorous demands of its customers. Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited to have completed our first commercial order and we are proud of the quality of distillate that our extraction team has produced in our new, world-class facility.”
Or, look at Aleafia Health Inc. (TSX:AH)(OTC:ALEAF). The company recently announced it will commence cannabis exports to the Israeli medical cannabis market. The Company signed a binding letter of intent with Equinox International Ltd., a licensed British medical cannabis company with operations in the Israeli market. Under the LOI, Equinox has committed to purchasing approximately 1,400 kg of dried flower in 2021. The first shipment to Equinox is expected to occur in Q1 2021 pending receipt of necessary import and export permits and completion of Aleafia’s cultivation cycle. Permit applications have already been submitted and will mark the first export of EU GACP-compliant dried flower grown at Aleafia’s Niagara Greenhouse facility.
Canopy Growth Corporation (NASDAQ:CGC)(TSX:WEED) announced the launch of a new line of science-backed CBD products for dogs under the brand name SurityPro. Leading scientists at Canopy Animal Health developed this new generation of advanced pet specialty CBD products for dogs to support calm behavior, joint health and flexibility, healthy aging, and overall physical and mental well-being in dogs. The SurityPro portfolio is scientifically-formulated to deliver carefully controlled CBD content for customized daily use in dogs of all sizes. All SurityPro CBD Pet products carry the National Animal Supplement Council (NASC) quality seal, denoting strict adherence to manufacturing, labeling, testing and marketing guidelines. The products also contain no corn, soy, artificial flavors, colors or preservatives.
Tilray Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, announced it has agreed with Worldpharma Biotech through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17th country to receive Tilray medical cannabis worldwide. The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain.
Trulieve Cannabis Corp. (CSE:TRUL)(OTC:TCNNF), a leading and top-performing cannabis company based in the United States, announced the expansion of its Blue River™ extracts lineup with Cold Cure Live Rosin. This newest addition to the Blue River products sold in Trulieve stores across Florida will be our most premium concentrate offering to date. Cold Cure Live Rosin is a solventless extract offering a balanced experience between flavor, effect, and potency with extreme purity. Blue River’s Cold Cure Live Rosin uses only Trulieve’s premium quality flower. Using live cannabis harvesting practices and ice water extraction methods preserves a higher concentration of the naturally occurring terpenes resulting in an extract that offers a premium grade of rosin with a higher concentration of flavor, broader range of effects, and overall better consistency.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Pure Extracts Technologies Corp. by a third party. We own ZERO shares of Pure Extracts Technologies Corp. Please click here for full disclaimer.